Sorrento Therapeutics Inc (SRNE)

[dia76ca]

Paulsnowman always shares some interesting thoughts!
Here are some of his thoughts today.

"1.PD-L1 (China) - the NDA application was Nov 1, and there’s a 90 day window for approval response. So sometime Jan

2. Abivertinib NSCLC (China) - application was DEC 2020. Past due for approval response. Given SRNE BO ACEA I would expect they know the data is good, and approval expected.

3. Scilex - SPAC expected Feb / March. Should fully expect SP102 full readout before SPAC. Most likely Jan.

4. STIX - increased orders / contracts from MX and Brazil. 4th quarter earnings (Est. Feb 18) revenue estimate is 13M. I expect the actual numbers to be significantly higher.

On another note, you know that FortuneBio opened a second manufacturing facility because of the high demand for diagnostic tests. SRNE has the option to purchase 51% of FortuneBio. I wonder if SRNE exercised it?

Abivertinib NSCLC (US) approval likely this year, and let’s not forget that eventually there will be a BO / partnership.

Sofusa - it may be still in P1, but if the technology works with Enbrel (Amgen) you can expect a BO / partnership sooner than later.

In short know what you own. My antenna goes up when all someone ever talks about is a possible STIX US EUA / PSS Arbitration settlement. That’s the manipulation game. We have not one, but two blockbuster drug approvals likely this year. Note - we have the Longwood, HC Wainwright, and JP Morgan conferences all pretty much one after another. I would expect some type of news, and definitely a more updated presentation this week or next."